Automated Insulin DeliveryAutomation for Better Control
An automated insulin delivery (AID) system is made up of an insulin pump, a continuous glucose monitoring (CGM) sensor, and predictive technology (an algorithm) that can predict glucose levels and automatically deliver or suspend insulin. Control-IQ+ technology is an advanced hybrid closed-loop system with predictive AutoBolus.
CGM Data
The CGM delivers real-time glucose readings to the insulin pump via Bluetooth® connectivity.
Predictive Algorithm
Control-IQ+ uses those readings and determines whether to deliver or suspend insulin approximately every 5 minutes.
Insulin Pump
Provides a steady release of basal insulin throughout the day and allows for bolusing for meals.
Explore automated insulin delivery and how it works.
Control-IQ+ Technology
Tested. Trusted. Better.
Tandem pumps are now powered by Control-IQ+ — the only predictive algorithm with AutoBolus. It's our best algorithm yet!
Best-In-Class Outcomes
Time in Range1*
According to real-world results
Said it’s Easy to Use2
According to clinical study participants
Tandem Mobi System
This insulin pump can be worn almost anywhere,† giving you more options for how you manage your diabetes. It’s powered by Control-IQ+ and is controllable with a compatible, personal iPhone.‡
t:slim X2 Insulin Pump
Sleek and modern, this all-in-one pump is easy to use, has a color touchscreen, and it pairs with multiple CGM sensors.§ It's powered by Control-IQ+, which predicts and helps prevent highs and lows.
A Tandem Diabetes Care Specialist will help you get started.
* With optimized Correction Factor based on “rule of less than 1600.”
† Do not wear or place your pump more than 12 inches (30.5 cm) above your infusion site. Doing so may result in over delivery of insulin.
‡ The mobile app requires a compatible smartphone model and operating system (sold separately). Only available to pump users who reside in the United States.
§ CGM sold separately.
References
Note: Studies were conducted using a t:slim X2 insulin pump with Control-IQ technology and Dexcom G6.
1. Messer LH, Breton M. Diabetes Technol Ther. 2023;25(12):877-882.
2. Kudva YC, et al. Diabetes Technol Ther. 2021;23(10):673-683.
Important Safety Information
RX ONLY.
Indications for Use
Tandem Mobi system: The Tandem Mobi insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The Pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater.
t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater.
Control-IQ+ technology: Control-IQ+ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ+ technology is intended for the management of type 1 diabetes mellitus in persons 2 years of age and greater and of type 2 diabetes mellitus in persons 18 years of age and greater.
Warning: Control-IQ+ technology should not be used in anyone under the age of 2 years old with type 1 diabetes or under the age of 18 years old with type 2 diabetes. It should also not be used in patients who require less than a total daily insulin dose of 5 units of insulin per day or who weigh less than 20 pounds (9 kilograms), as those are the required minimum values needed for Control-IQ+ to operate safely.
Users of the pump and Control-IQ+ must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use. Failure to follow these instructions for use could result in an over delivery or under delivery of insulin. This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Visit tandemdiabetes.com/safetyinfo for additional important safety information.